Cognition Therapeutics (CGTX) Cash from Financing Activities (2020 - 2026)
Cognition Therapeutics (CGTX) reported Cash from Financing Activities of -$233000.0 for Q1 2026, down 117.98% year-over-year from $1.3 million in Q1 2025, and down 138.51% on a QoQ basis from $605000.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Cash from Financing Activities data on file, last reported at -$233000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 117.98% year-over-year to -$233000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.0 million (up 172.31% YoY) and the FY2025 annual result came in at $36.6 million, up 55.19% from the prior year.
- Cash from Financing Activities slipped to -$233000.0 in Q1 2026 per CGTX's latest filing, from $605000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $33.9 million in Q3 2025 and bottomed at -$374000.0 in Q2 2022.
- The 5-year median for Cash from Financing Activities is $752000.0 (2025), against an average of $4.1 million.
- The widest annual swing landed in 2024, when Cash from Financing Activities jumped 120030.0%; it then tumbled 117.98% in 2026.
- Tracing CGTX's Cash from Financing Activities over 5 years: stood at $5.1 million in 2022, then plunged by 52.57% to $2.4 million in 2023, then soared by 366.63% to $11.4 million in 2024, then tumbled by 94.68% to $605000.0 in 2025, then plunged by 138.51% to -$233000.0 in 2026.
- Per Business Quant, the three latest CGTX Cash from Financing Activities figures stand at -$233000.0 (Q1 2026), $605000.0 (Q4 2025), and $33.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -233,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -233,000.00 |
| Mar 31, 2026 | -233,000.00 |
| Dec 31, 2025 | 605,000.00 |
| Dec 31, 2025 | 605,000.00 |
| Sep 30, 2025 | 33.92 Mn |
| Sep 30, 2025 | 33.92 Mn |
| Jun 30, 2025 | 752,000.00 |
| Jun 30, 2025 | 752,000.00 |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 11.38 Mn |
| Dec 31, 2024 | 11.38 Mn |
| Sep 30, 2024 | 329,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Mar 31, 2024 | 11.99 Mn |
| Mar 31, 2024 | 11.99 Mn |
| Dec 31, 2023 | 2.44 Mn |
| Dec 31, 2023 | 2.44 Mn |
| Sep 30, 2023 | -3,000.00 |
| Sep 30, 2023 | -3,000.00 |
| Jun 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | -10,000.00 |
| Mar 31, 2023 | -10,000.00 |
| Dec 31, 2022 | 5.14 Mn |
| Dec 31, 2022 | 5.14 Mn |
| Sep 30, 2022 | 869,000.00 |
| Sep 30, 2022 | 869,000.00 |
| Jun 30, 2022 | -374,000.00 |
| Jun 30, 2022 | -374,000.00 |
| Mar 31, 2022 | -91,000.00 |
| Mar 31, 2022 | -91,000.00 |
| Dec 31, 2021 | 46.36 Mn |
| Dec 31, 2021 | 46.36 Mn |
| Sep 30, 2021 | -961,000.00 |
| Sep 30, 2021 | -961,000.00 |
| Jun 30, 2021 | -1.16 Mn |
| Jun 30, 2021 | -1.16 Mn |
| Mar 31, 2021 | 8.96 Mn |
| Mar 31, 2021 | 8.96 Mn |
| Dec 31, 2020 | 445,000.00 |
| Dec 31, 2020 | 445,000.00 |